Background: Selected proton pump inhibitors (PPI) interfere with clopidogrel metabolism, potentially attenuating P2Y12 receptor-based platelet inhibition. Previous observational and randomized trials have reported varying results regarding the clinical significance of this pharmacologic interaction. We examined this relationship in the large-scale, prospective Assessment of Dual Anti-Platelet Therapy with DrugEluting Stents (ADAPT-DES) study. Methods: Platelet reactivity testing was performed using the VerifyNow point-of-care assay in 8,583 patients at 11 US and German sites after successful DES implantation. All patients were treated with aspirin and clopidogrel, and were followed for 1 year. PPI were prescribed at the discretion of treating physicians. Results: At the time of the post-procedure P2Y12 test, 2,697 (31.4%) pts were on PPI, and 5,886 (68.6%) were not. Major baseline characteristics, P2Y12 results and 1-year events are summarized in the Table. The use of PPI was an independent predictor of higher platelet reactivity (HPR) units (PRU) in a linear regression model (p<0.0001), and additionally was independently associated with HPR as defined as PRU>208 (OR 1.38 [1.25, 1.52], p¼0.0001). At discharge, 2,163 (25.2%) pts were prescribed PPI, and 6,419 (74.8%) were not. In propensity-adjusted proportional hazards regression models, PPI use was independently associated with out of hospital mortality (HR 1.52 [1.09, 2.12], p¼0.01) and MACE (HR 1.23 [1.00, 1.51], p¼0.049).
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Conclusions: In patients treated with clopidogrel after DES, the concomitant administration of PPI is associated with reduced platelet inhibition and adverse clinical outcomes. Additional studies are warranted to determine the risk-benefit ratio of PPI in patients after DES. We studied use of prasugrel vs. clopidogrel among 11,417 STEMI and NSTEMI patients treated with PCI in the TRANSLATE-ACS study from 4/2010 to 10/2012. We used multivariable Cox models to compare 30-day MACE (death, recurrent MI, stroke, or unplanned revascularization) and any GUSTO defined bleeding. Results: Prasugrel was used in 2,997 MI patients (26%) during PCI. Patients treated with prasugrel were younger (median 57 vs. 61 yrs), more likely to present with STEMI (59% vs. 49%), and less likely to have prior MI (15% vs. 21%) or diabetes (24% vs. 27%) than those receiving clopidogrel (p<0.01 for all). Prasugrel was used in 57 (9%) of patients with prior stroke/TIA, 64 (5%) over age 75, and 74 (14%) of patients <60 kg. Compared with clopidogrel, prasugrel was more often started during/ after PCI, and used with bivalirudin or GPIIb/IIIa inhibitor. Unadjusted curves for 30-day MACE and bleeding diverged, but were not significantly different between prasugrel and clopidogrel treated patients (Figure) . Multivariable analyses did not demonstrate significant differences in MACE (HR 0.96, 95%CI 0.79, 1.16) and bleeding (HR 1.04, 95%CI 0.77, 1.39). Conclusions: While differences exist in patients receiving these drugs, the 30-day effectiveness and safety of prasugrel vs. clopidogrel were not significantly different in routine practice. Long-term outcomes comparisons are necessary and ongoing.
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